Scholarlink

Purpose of Review <p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used by increasing numbers of patients, but may adversely affect the safety of endoscopic procedures, due to their association with decreased gastrointestinal motility.</p> Recent Findings <p>GLP-1RA use increases the incidence of retained gastric contents found on upper endoscopy and aborted upper endoscopic procedures. There is mounting evidence that in clinical settings, this does not translate into significantly increased risk of pulmonary aspiration. GLP-1RA use likely also increases the risk of incomplete bowel prep during colonoscopy. Strategies to mitigate the retained gastric contents include a prolonged fasting period from solid food (up to 24&#xa0;h), but holding doses of GLP-1RAs is not routinely beneficial. No such strategies have been tested in a rigorous, controlled, prospective fashion.</p> Summary <p>Some modifications of the preparation for patients undergoing endoscopic procedures while using GLP-1RAs are reasonable. However, growing evidence suggests these modifications need not be as burdensome as proposed in the recent past. Research must continue to assess how best to protect the increasing numbers of endoscopy patients using increasingly potent GLP-1RA agents.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GLP-1 Receptor Agonists and Endoscopic Procedural Optimization: How To Minimize Risk and Improve Outcomes

  • 期刊论文

  • 发表日期：

    2025年6月13日

查看全文
  • Trevor S. Barlowe,
  • Lindsey N. Gouker,
  • John B. Buse,
  • Robert S. Sandler,
  • Michael K. Dougherty

摘要

Purpose of Review

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used by increasing numbers of patients, but may adversely affect the safety of endoscopic procedures, due to their association with decreased gastrointestinal motility.

Recent Findings

GLP-1RA use increases the incidence of retained gastric contents found on upper endoscopy and aborted upper endoscopic procedures. There is mounting evidence that in clinical settings, this does not translate into significantly increased risk of pulmonary aspiration. GLP-1RA use likely also increases the risk of incomplete bowel prep during colonoscopy. Strategies to mitigate the retained gastric contents include a prolonged fasting period from solid food (up to 24 h), but holding doses of GLP-1RAs is not routinely beneficial. No such strategies have been tested in a rigorous, controlled, prospective fashion.

Summary

Some modifications of the preparation for patients undergoing endoscopic procedures while using GLP-1RAs are reasonable. However, growing evidence suggests these modifications need not be as burdensome as proposed in the recent past. Research must continue to assess how best to protect the increasing numbers of endoscopy patients using increasingly potent GLP-1RA agents.